Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

17 May 2017 07:00

RNS Number : 3487F
Ideagen PLC
17 May 2017
 

This announcement contains inside information.

 

 

17 May 2017

 

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, is pleased to provide an update on trading for the year ended 30 April 2017 ahead of the announcement of its full year results on or around 18 July 2017.

 

The Board is pleased to report that results to 30 April 2017 are expected to be in line with market expectations and that trading was once again robust across all key verticals, with particular success within the Life Sciences, Aviation and Financial sectors. The Group delivered organic revenue growth* of approximately 10 per cent together with further contributions from all four acquisitions made during the year. This represents the Group's eighth consecutive year of revenue and adjusted EBITDA** growth.

 

The Group expects to report revenue of approximately £27.1million, (FY2016: £21.9 million) and adjusted EBITDA** of approximately £7.8 million (FY2016: £6.3 million), both having increased by approximately 24%, and a significant increase in adjusted EPS***, which continues to be an important financial metric for the Group.

 

The Board is confident that the transition from a traditional 'perpetual licence' business model to a 'subscription licence' model is well underway, as evidenced by a significant increase in the run-rate of recurring revenues. This has been driven primarily by the success of Coruson, our SaaS based enterprise Risk and Safety Management solution which is allowing the Group to win larger contracts and grow high visibility, subscription-based revenue. 

 

Cash generation was extremely strong at the end of the financial year and accordingly net cash at 30 April 2017 was significantly ahead of market forecasts at £4.2 million (31 October 2016: £4.8 million), even after paying £4.6 million of consideration for the acquisitions of IPI Solutions and Gael (deferred) and £0.3 million in dividends. The Board expects to report that cash generated by operations will be in excess of 100% of adjusted EBITDA**.

 

 

David Hornsby, Chief Executive, commented: "We are pleased to report that the Group has continued to perform well in delivering another year of high quality earnings growth underpinned by strong cash generation. We have also made four important acquisitions which have provided scale, product capability and recurring revenues. We continue to grow organically and to increase the percentage of our revenues derived from recurring business. The Group has significant contracted work in progress and a strong pipeline of new business opportunities which provides the Board with confidence for the current year and beyond."

 

* FY2016 comparator prepared on a proforma basis as if these acquisitions had occurred during that year

**Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and other exceptional items.

***Adjusted diluted earnings per share

 

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Chief Executive

 

Graeme Spenceley, Finance Director

 

 

 

finnCap Limited

020 7220 0500

Stuart Andrews/Henrik Persson/James Thompson (Nomad)

 

Stephen Norcross (Corporate Broking)

 

 

 

 

 

 About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in GRC (Governance, Risk and Compliance) and Content and Clinical solutions with a primary focus on organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete information lifecycle solutions that enable organisations to reduce risk, meet their regulatory and compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 3,000 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDQLFFDEFXBBK
Date   Source Headline
14th Oct 20215:46 pmRNSIssue of new shares under the SIP
14th Oct 20217:00 amRNSSale of Pentana Compliance
11th Oct 20212:25 pmRNSNotice of AGM
1st Oct 20213:15 pmRNSTotal Voting Rights
1st Oct 20217:00 amRNSChange of Auditor
24th Sep 20219:37 amRNSIssue of Shares, PDMR Dealing & TVR
13th Sep 20214:50 pmRNSExercise of Options and Total Voting Rights
10th Sep 20216:05 pmRNSHolding(s) in Company
2nd Sep 20217:00 amRNSTotal Voting Rights
31st Aug 20219:32 amRNSHolding(s) in Company
26th Aug 20217:00 amRNSPDMR Dealing and Total Voting Rights
11th Aug 20212:02 pmRNSIssue of new shares under the SIP and TVR
11th Aug 20217:00 amRNSExercise of Options and Total Voting Rights
23rd Jul 20214:54 pmRNSPDMR Dealing and Total Voting Rights
22nd Jul 20217:00 amRNSFinal Results
20th Jul 20212:03 pmRNSIssue of new shares under the SIP
19th Jul 20217:00 amRNSTwo highly complementary strategic acquisitions
15th Jul 20214:17 pmRNSExercise of share options and Total Voting Rights
16th Jun 20217:00 amRNSIssue of new shares under the SIP
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:36 pmRNSPrice Monitoring Extension
21st May 20217:00 amRNSDirector/PDMR Shareholding
13th May 20217:00 amRNSPre-Close Trading Update and Board Change
28th Apr 20217:00 amRNSDirector Dealings and Total Voting Rights
14th Apr 202112:40 pmRNSIssue of Shares, PDMR Dealing & TVR
16th Mar 20213:33 pmRNSIssue of new shares under the SIP and TVR
9th Mar 20217:00 amRNSAcquisition of Qualtrax
26th Feb 20211:49 pmRNSHolding(s) in Company
25th Feb 20214:00 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSHolding(s) in Company
23rd Feb 20217:00 amRNSPDMR Dealing and Total Voting Rights
16th Feb 20215:15 pmRNSIssue of Equity & Total Voting Rights
12th Feb 20217:00 amRNSDirector/PDMR Dealings
3rd Feb 20219:35 amRNSExtension to 2018 LTIP Awards
26th Jan 20217:00 amRNSSuccession of Chairman
26th Jan 20217:00 amRNSUnaudited Interim Results
25th Jan 20214:26 pmRNSH1 Results Presentation
22nd Jan 20217:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
31st Dec 20207:00 amRNSHolding(s) in Company
30th Dec 20207:21 amRNSCompletion of Huddle Acquisition
23rd Dec 202011:30 amRNSAcquisition of Huddle
22nd Dec 20202:04 pmRNSHolding(s) in Company
18th Dec 202012:56 pmRNSIssue of Shares & Director/PDMR Shareholding
9th Dec 20207:00 amRNSResult of Placing and PrimaryBid Offer
8th Dec 20204:53 pmRNSPrimaryBid.com Offer
8th Dec 20204:50 pmRNSProposed Fundraise of £48.7 million
20th Nov 20203:40 pmRNSIssue of Equity, PDMR Dealing and TVR
17th Nov 202012:05 pmRNSChange of Registered Office
13th Nov 20203:51 pmRNSPDMR Shareholding and Exercise of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.